May 5, 2004 Volume 6 / Number 17 Dear Colleague: There is still time for pro-lifers to call the White House (202-456-1414) and urge the President to assure the American people that the mega dose “morning after pill” will not be sold “over the counter.”
23 de Abril del 2004 Volumen 6/Número 16 Estimado amigo: USAID está pidiendo terminar con la promiscuidad sexual en el extranjero, con el objeto de detener la expansión del HIV/SIDA. Al mismo tiempo, sin embargo, USAID está promoviendo la promiscuidad sexual bajo la modalidad de
April 23, 2004 Volume 6 / Number 16 Dear Colleague: USAID is calling for an end to sexual promiscuity overseas, in order to stop the spread of HIV/AIDS. At the same time, however, USAID is promoting sexual promiscuity in the form of over-the-counter distribution of
April 16, 2004 Volume 6 / Number 15 Dear Colleague: Over-the-counter (OTC) availability of the morning-after pill (MAP)-so called “emergency contraception” or EC- would increase rates of abortion, disease, sexual promiscuity, and sexual violence committed against American teens. OTC/MAP means danger for American girls. Steven
April 8, 2004 Volume 6 / Number 14 Dear Colleague: A new report by the U.S. Census Bureau warns that the rate of world population growth is continuing to fall. Mortality rates increase. Fertility rates continue to fall. Population collapse is just around the corner.
April 2, 2004 Volume 6 / Number 13 Dear Colleague: The efforts to pressure the U.S. Food and Drug Administration (FDA) into approving the morning-after pill (MAP) for over-the-counter (OTC) distribution are inextricably linked to the international abortion industry. The founder of Women’s Capital Corporation,
March 26, 2004 Volume 6 / Number 12 Dear Colleague: On February 20, 2004, the Food and Drug Administration (FDA) announced it would delay for 90 days its decision to approve over-the-counter (OTC) status of the morning-after pill (MAP). The FDA said it needed more
March 19, 2004 Volume 6 / Number 11 Dear Colleague: In rejecting Plan B’s application to approve the morning-after abortion pill (MAP) for over-the-counter (OTC) distribution, the FDA should also designate this chemical as an abortion drug. The medical establishment, which has abandoned the science
Dear Colleague: PRI is a proud co-sponsor of this year’s World Congress of Families (III), which takes place on March 29-31, 2004, in Mexico City, Mexico. This is the world’s largest conference of pro-family leaders and grass-roots activists, bar none. More than 2,000 family activists
March 5, 2004 Volume 6 / Number 9 Dear Colleague: Last month, the U.S. Food and Drug Administration (FDA) delayed until May its decision on Women’s Capital Corporation’s application for over-the-counter (OTC) status for the morning-after pill, so-called emergency contraception (EC). In order to educate
May 5, 2004 Volume 6 / Number 17 Dear Colleague: There is still time for pro-lifers to call the White House (202-456-1414) and urge the
23 de Abril del 2004 Volumen 6/Número 16 Estimado amigo: USAID está pidiendo terminar con la promiscuidad sexual en el extranjero, con el objeto de
April 23, 2004 Volume 6 / Number 16 Dear Colleague: USAID is calling for an end to sexual promiscuity overseas, in order to stop the
April 16, 2004 Volume 6 / Number 15 Dear Colleague: Over-the-counter (OTC) availability of the morning-after pill (MAP)-so called “emergency contraception” or EC- would increase
April 8, 2004 Volume 6 / Number 14 Dear Colleague: A new report by the U.S. Census Bureau warns that the rate of world population
April 2, 2004 Volume 6 / Number 13 Dear Colleague: The efforts to pressure the U.S. Food and Drug Administration (FDA) into approving the morning-after
March 26, 2004 Volume 6 / Number 12 Dear Colleague: On February 20, 2004, the Food and Drug Administration (FDA) announced it would delay for
March 19, 2004 Volume 6 / Number 11 Dear Colleague: In rejecting Plan B’s application to approve the morning-after abortion pill (MAP) for over-the-counter (OTC)
Dear Colleague: PRI is a proud co-sponsor of this year’s World Congress of Families (III), which takes place on March 29-31, 2004, in Mexico City,
March 5, 2004 Volume 6 / Number 9 Dear Colleague: Last month, the U.S. Food and Drug Administration (FDA) delayed until May its decision on